London
· Delayed Price · Currency is GBP · Price in USDGilead Sciences Company Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies.
The company was incorporated in 1987 and is headquartered in Foster City, California.
| Country | United States |
| Founded | 1987 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 18,000 |
| CEO | Daniel P. O'Day |
Contact Details
Address: 333 Lakeside Drive Foster City, Delaware 94404 United States | |
| Phone | 650 574 3000 |
| Website | gilead.com |
Stock Details
| Ticker Symbol | 0QYQ |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel P. O'Day | Chairman and Chief Executive Officer |
| Andrew D. Dickinson | Chief Financial Officer |
| Deborah H. Telman J.D. | Executive Vice President of Corporate Affairs, General Counsel and Corporate Secretary |
| Johanna Mercier | Chief Commercial Officer |
| Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer |
| Sandra Patterson | Senior Vice President, Corporate Controller and Principal Accounting Officer |
| Jacquie Ross C.F.A. | Vice President of Investor Relations |
| Jyoti K. Mehra | Executive Vice President of Human Resources |
| Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation and Portfolio |
| Dr. Rudolf Ertl | Senior Vice President of Commercial Operations of Australia, Canada, Europe |